Clinical Trial Update: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Lasofoxifene plus Abemaciclib versus Fulvestrant plus Abemaciclib in locally advanced or metastatic ER-positive, HER2-negative breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• Lasofoxifene (Lasofoxifene)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: LeonaBio | Conditions: Metastatic Breast Cancer | Phase 3 | Status: RECRUITING